Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Jaen – page 4

132 clinical trials in Jaen, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Jaen at a glance
132
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

132 trials in Jaen

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Neoplasm malignant

Recruiting

Study of ART6043, Olaparib, and Niraparib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ART6043
  • Sponsor:Artios Pharma Limited

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Obesity

Recruiting

Study on Levothyroxine and Low-Calorie Diet for Weight Loss in Obese Patients with Subclinical Hypothyroidism or High-Normal TSH Levels

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Levothyroxine Sodium
  • Sponsor:Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Alisertib with Hormone Therapy for Patients with HR+, HER2- Recurrent or Metastatic Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alisertib Sodium
  • Sponsor:Puma Biotechnology Inc.

Hepatocellular carcinoma

Recruiting

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Endometrial cancer+3

Recruiting

Study of E7386 and Lenvatinib for Patients with Liver, Colon, Endometrial, or Other Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Eisai Limited

Lung neoplasm malignant+2

Recruiting

Study on Niraparib with Immunotherapy for Patients with SLFN11-Positive Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:ETOP IBCSG Partners Foundation

Ovarian cancer

Recruiting

Study on the Effectiveness of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients with Limited Metastasis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Medica Scientia Innovation Research S.L.

Non-small cell lung cancer

Recruiting

Study on the Safety and Effectiveness of Zipalertinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Specific EGFR Mutations

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Digoxin
  • Sponsor:Taiho Oncology Inc.

Non-small cell lung cancer

Recruiting

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Metastatic malignant melanoma

Recruiting

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Jaen

What the registry says about research in the country

01 Lung Cancer Research

Multiple studies focusing on non-small cell lung cancer and small cell lung cancer treatments, investigating novel combination therapies and targeted approaches for different disease stages.

  • EGFR mutation treatments
  • Immunotherapy combinations
  • Chemotherapy optimization

Research emphasizes improving survival rates through innovative therapeutic approaches for both extensive and limited-stage disease.

02 Breast Cancer Innovations

Comprehensive research into HER2-positive and hormone receptor-positive breast cancer, exploring new treatment combinations and targeted therapies.

  • Endocrine therapy combinations
  • Immunotherapy applications
  • Targeted molecular treatments

Studies focus on both early-stage and metastatic disease, with emphasis on personalized treatment approaches.

03 Specialized Cancer Studies

Diverse research covering hepatocellular carcinoma, bladder cancer, and other solid tumors, evaluating novel therapeutic strategies.

  • Immunotherapy innovations
  • Combination treatment approaches
  • Disease-specific therapies

Investigations aim to improve treatment outcomes across multiple cancer types using cutting-edge therapeutic approaches.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.